Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients

Arlene M. Gallagher; Efrosini Setakis; Jonathan M. Plumb; Andreas Clemens; Tjeerd-Pieter van Staa

doi:10.1160/TH11-05-0353

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2011; 106(05): 968-977
DOI: 10.1160/TH11-05-0353

New Technologies, Diagnostic Tools and Drugs

Schattauer GmbH

Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients

Arlene M. Gallagher

¹General Practice Research Database, Medicines and Healthcare products Regulatory Agency, London, UK

,

Efrosini Setakis

¹General Practice Research Database, Medicines and Healthcare products Regulatory Agency, London, UK

,

Jonathan M. Plumb

³Boehringer Ingelheim, Ingelheim am Rhein, Germany

,

Andreas Clemens

³Boehringer Ingelheim, Ingelheim am Rhein, Germany

,

Tjeerd-Pieter van Staa

¹General Practice Research Database, Medicines and Healthcare products Regulatory Agency, London, UK

²Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands

› Institutsangaben

Abstract

als PDF herunterladen

Summary

Atrial fibrillation (AF) carries an increased risk of ischaemic stroke, and oral anticoagulation with warfarin can reduce this risk. The objective of this study was to evaluate the association between time in therapeutic International Normalised Ratio (INR) range when receiving warfarin and the risk of stroke and mortality. The study cohort included AF patients aged 40 years and older included in the UK General Practice Research Database. For patients treated with warfarin we computed the percentage of follow-up time spent within therapeutic range. Cox regression was used to assess the association between INR and outcomes while controlling for patient demographics, health status and concomitant medication. The study population included 27,458 warfarintreated (with at least 3 INR measurements) and 10,449 patients not treated with antithrombotic therapy. Overall the warfarin users spent 63% of their time within therapeutic range (TTR). This percentage did not vary substantially by age, sex and CHA₂DS₂-VASc score. Patients who spent at least 70% of time within therapeutic range had a 79% reduced risk of stroke compared to patients with ≤30% of time in range (adjusted relative rate of 0.21; 95% confidence interval 0.18–0.25). Mortality rates were also significantly lower with at least 70% of time spent within therapeutic range. In conclusion, good anticoagulation control was associated with a reduction in the risk of stroke.

Keywords

Atrial fibrillation - anticoagulation - stroke - treatment - warfarin

PDF (210 kb)

Referenzen

References
1 Fuster V, Rydén LE, Cannom DS. et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-354.
2 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
3 Rietbrock S, Plumb JM, Gallagher AM. et al. How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. Thromb Haemost 2009; 101: 527-534.
4 Fang MC, Go AS, Hylek EM. et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc 2006; 54: 1231-1236.
5 Hylek EM, Go AS, Chang Y, Jensvold NG. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
6 van Walraven C, Jennings A, Oake N. et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129: 1155-1166.
7 Jones M, McEwan P, Morgan CL. et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91: 472-477.
8 Currie CJ, Jones M, Goodfellow J. et al. Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Heart 2006; 92: 196-200.
9 Morgan CL, McEwan P, Tukiendorf A. et al. Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. Thromb Res 2009; 124: 37-41.
10 Gallagher AM, Rietbrock S, Plumb J. et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?. J Thromb Haemost 2008; 6: 1500-1506.
11 Parkinson J, Davis S, van Staa TP. The General Practice Research (GPRD) Database: Now and the Future. In Pharmacovigilance 2007, 2nd ed John Wiley; Sons:
12 Rosendaal FR, Cannegieter SC, van der Meer FJ. et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
13 Gage BF, Waterman AD, Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864-2870.
14 Lip GYH, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 2010; 137: 263-272.
15 Gladstone DJ, Bui E, Fang J. et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009; 40: 235-240.
16 Samsa GP, Matchar DB, Goldstein LB. et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000; 160: 967-973.
17 Cohen N, Almoznino-Sarafian D, Alon I. et al. Adequacy of anticoagulation in patients with atrial fibrillation: effect of various parameters. Clin Cardiol 2001; 24: 380-384.
18 Connolly SJ, Pogue J, Eikelboom J. et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
19 Hixson-Wallace JA, Dotson JB, Blakey SA. Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy. Clin Appl Thromb Hemost 2001; 7: 33-37.
20 Yang DT, Robetorye RS, Rodgers GM. Home prothrombin time monitoring: a literature analysis. Am J Hematol 2004; 77: 177-186.
21 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
22 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
23 Hobbs FD, Roalfe AK, Lip GY. et al. on behalf of the Birmingham Atrial Fibrillation in the Aged (BAFTA) investigators and Midland Research Practices Consortium (MidReC) network. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. Br Med J 2011; 342: d3653 doi: 10.1136/bmj.d3653
24 van Staa TP, Setakis E, Di Tanna GL. et al. A comparison of risk stratification schema for stroke in 79884 atrial fibrillation patients in general practice. J Thromb Haemost 2010; 9: 39-48.
25 Olesen JB, Lip GY, Hansen ML. et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. Br Med J 2011; 342: d124 doi: 10.1136/bmj.d124
26 Lip GY, Frison L, Halperin JL. et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41: 2731-2738.
27 Ruigómez A, Johansson S, Wallander M-A. et al. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 2002; 55: 358-363.
28 Rietbrock S, Heeley E, Plumb J. et al. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 2008; 156: 57-64.